However, when distinguishing GC patients at stage I and II from controls, the AUC for the serum SPRR2A was a little bit lower, 0.78 (95% CI = 0.669–0.891; sensitivity: 69.6%; specificity: 68.1%), indicating that SPRR2A is not among the best EGC biomarkers. This evidence concerns the gene SPRR2A and gastric cancer.